“High SARS-CoV-2 seroprevalence but no severe course of COVID-19 disease among people on opioid agonist treatment in Zurich: a cross-sectional study”, Swiss Med Wkly, vol. 152, no. 0102, p. w30122, Jan. 2022, doi: 10.4414/SMW.2022.w30122.